Navigation Links
Another Treatment Option for Benign Tumors

A recent study shows treating benign tumors outside the brain using the CyberKnife frameless radiosurgery can successfully // control their growth and progression with minimal toxicity. CyberKnife is a non-invasive robotic radiosurgical device that can remove tumors and other lesions without open surgery. It uses a robotic arm, controlled by a computer, that sends multiple beams of high-dose radiation directly to the tumor site.

During the study researchers examined the feasibility, toxicity and tumor control of patients with symptomatic benign tumors in the spine, neck, skull, eye and brainstem treated with CyberKnife. 50 benign tumors in 35 patients who underwent radiosurgery were evaluated. Seventy-eight percent of patients treated with CyberKnife had an improvement of their pre-treatment symptoms including pain and weakness. Tumor growth was 96-percent controlled locally for the 26 patients who had follow-up imaging for up to 25 months after treatment. CyberKnife was also able to control aggressive benign tumors that had progressed despite surgery and/or conventional radiation.

Thus researchers say their findings demonstrate that CyberKnife may offer a promising treatment option for patients with benign tumors who are not candidates for surgery or whose tumors are not amendable to surgery .
'"/>




Page: 1

Related medicine news :

1. Another ray of hope for Arthritis Sufferers
2. Another injectable contraceptive Pill approved by FDA
3. The Possibility Of Fighting HIV with Another Virus Questioned
4. New Research Has Found Another Use For Botox
5. Yet Another Harmful Consequence Of Smoking
6. Yet Another Treatment Option For Cancer
7. Another Alternative For Diabetics On Insulin
8. Another Use For Epilepsy Drugs
9. Another Cause of Thyroid Cancer Discovered
10. Yet Another Use For Cell Phone Cameras
11. Yet Another Use For Cocoa Flavonols
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing ... B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads based ... of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the sales ...
(Date:2/26/2017)... ... 2017 , ... ODH, Inc.™ announced today it will exhibit and speak ... City Hotel in Arlington, VA. ODH’s director of medical strategy, Candace Saldarini, M.D., will ... Medicaid population health management. , ODH will also have an exhibit booth where attendees ...
(Date:2/26/2017)... ... 2017 , ... Occupational pesticide exposure is linked to an ... according to a study released today at the 1st Pan American Parkinson’s and ... pesticides and incidence of sporadic PD through occupational exposure. This latest study, led ...
(Date:2/24/2017)... ... February 24, 2017 , ... HealthPostures, expert ... Core benefits and advantages built into the home office sit stand solution are ... feel. Ability to gain the benefits embedded in the TaskMate Go are available ...
(Date:2/24/2017)... ... ... two months after the official release of The Private Collection – Edition 2017 at ... a second print-run of its lavish luxury travel coffee table book. , An ... at more than six kilos, retails at EUR 1,000 per copy and is packed ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australien, 24. Februar 2017 ITL ... Unternehmen des Gesundheitsbereiches, ist erfreut, für das zum ... dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. ... Aktualisierung zum Wachstum" finden Sie hier . ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... 2017  Directors from Pharma To Market Pty Ltd and Ador ... resulting in the founding of Pharma To Market Pte Ltd, based ... are pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia ... Singapore based entity. Joelle brings with her an ...
(Date:2/24/2017)... 2017 Non-alcoholic steatohepataitis (NASH) Pipeline ... drugs being developed for the treatment of ... that are in various phases of development ... on novel pharmacologic drugs & regenerative medicines ... recombinant proteins and RNA-based therapeutics, but excludes ...
Breaking Medicine Technology: